Pulike Biological Engineering, Inc. (603566) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

The company declared positive results in Mar'25 after very negative results in Dec'24

OPERATING CASH FLOW(Y) Highest at CNY 319.58 MM
RAW MATERIAL COST(Y) Fallen by -2.82% (YoY)
PRE-TAX PROFIT(Q) Highest at CNY 65.67 MM

With ROE of 5.41%, it has a very attractive valuation with a 1.83 Price to Book Value

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

CNY 4,777 Million (Small Cap)

P/E

34.00

Industry P/E

Dividend Yield

2.96%

Debt Equity

-0.27

Return on Equity

5.41%

Price to Book

1.83

Revenue and Profits:

Net Sales:

277 Million

(Quarterly Results - Jun 2025)

Net Profit:

63 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-9.01%

6 Months

-13.55%

1 Year

-3.56%

2 Years

-38.38%

3 Years

-53.3%

4 Years

-29.81%

5 Years

-45.8%

Pulike Biological Engineering, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Pulike Biological Engineering, Inc. Reports Strong Financial Performance in Q1 2025

Pulike Biological Engineering, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reported a robust financial performance for the quarter ending March 2025. The company has achieved significant milestones in its financial metrics, indicating a positive trajectory for its operations.

One of the standout figures from the latest financial results is the operating cash flow, which reached its highest level at CNY 319.58 MM. This impressive cash flow performance underscores the company's ability to generate liquidity from its core operations, a crucial factor for sustaining growth and investment in future projects.

Additionally, Pulike Biological Engineering, Inc. has successfully managed its raw material costs, which have decreased by 2.82% year-over-year. This reduction in costs not only enhances the company's profitability but also ...

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

7.82%

EBIT Growth (5y)

3.16%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.26

Sales to Capital Employed (avg)

0.43

Tax Ratio

7.96%

Dividend Payout Ratio

148.09%

Pledged Shares

Institutional Holding

ROCE (avg)

9.93%

ROE (avg)

8.20%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.83

EV to EBIT

25.83

EV to EBITDA

14.51

EV to Capital Employed

2.14

EV to Sales

3.70

PEG Ratio

3.76

Dividend Yield

2.96%

ROCE (Latest)

8.28%

ROE (Latest)

5.41%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Bearish

Mildly Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.91% vs -0.83% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 19.66% vs 491.85% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "276.70",
          "val2": "274.20",
          "chgp": "0.91%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "97.50",
          "val2": "91.20",
          "chgp": "6.91%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.60",
          "val2": "-0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "63.30",
          "val2": "52.90",
          "chgp": "19.66%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "243.00%",
          "val2": "222.10%",
          "chgp": "2.09%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -17.13% vs 1.71% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -46.82% vs 3.99% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,026.00",
          "val2": "1,238.10",
          "chgp": "-17.13%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "225.60",
          "val2": "267.00",
          "chgp": "-15.51%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "1.10",
          "chgp": "-72.73%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-9.00",
          "val2": "-17.70",
          "chgp": "49.15%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "92.80",
          "val2": "174.50",
          "chgp": "-46.82%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "102.60%",
          "val2": "142.00%",
          "chgp": "-3.94%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

276.70

274.20

0.91%

Operating Profit (PBDIT) excl Other Income

97.50

91.20

6.91%

Interest

0.00

Exceptional Items

-0.60

-0.00

Consolidate Net Profit

63.30

52.90

19.66%

Operating Profit Margin (Excl OI)

243.00%

222.10%

2.09%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.91% vs -0.83% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 19.66% vs 491.85% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

1,026.00

1,238.10

-17.13%

Operating Profit (PBDIT) excl Other Income

225.60

267.00

-15.51%

Interest

0.30

1.10

-72.73%

Exceptional Items

-9.00

-17.70

49.15%

Consolidate Net Profit

92.80

174.50

-46.82%

Operating Profit Margin (Excl OI)

102.60%

142.00%

-3.94%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -17.13% vs 1.71% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -46.82% vs 3.99% in Dec 2023

All Annual Results

Company CV

About Pulike Biological Engineering, Inc.

Pulike Biological Engineering, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Pulike Biological Engineering, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

MarketsMojo — Loved in India, Now Global

Dashboard

The company declared positive results in Mar'25 after very negative results in Dec'24

With ROE of 5.41%, it has a very attractive valuation with a 1.83 Price to Book Value

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Pulike Biological Engineering, Inc. Reports Strong Financial Performance in Q1 2025

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About Pulike Biological Engineering, Inc.

Company Coordinates